Back to top

gene-therapy: Archive

Zacks Equity Research

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

VRTXNegative Net Change EDITPositive Net Change CRSPNegative Net Change ALXONegative Net Change

Zacks Equity Research

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.

VRTXNegative Net Change HTGCPositive Net Change BLUENegative Net Change CRSPNegative Net Change